On the design of complex drug candidate syntheses in the pharmaceutical industry

The overall goal of a process chemistry department within the pharmaceutical industry is to identify and develop a commercially viable approach to a drug candidate. However, the high chemical complexity of many modern pharmaceuticals presents a challenge to process scientists. Delivering disruptive, rather than incremental, change is critical to maximizing synthetic efficiency in complex settings. In this Review, we focus on the importance of synthetic strategy in delivering ‘disruptive innovation’ — innovation that delivers a step change in synthetic efficiency using new chemistry, displacing any prior synthetic route. We argue that achieving this goal requires visionary retrosynthetic strategy and is tightly linked to the discovery and development of new reactions and novel processes. Investing in high-risk innovation during the route design process can ultimately lead to safer, more robust and more efficient manufacturing processes capable of addressing the challenge of high molecular complexity. Routinely delivering such innovation in a time-bound environment requires organizational focus and can be enabled by the concepts of expansive ideation, strategy aggregation and strategy selection. The primary goal of a process chemist is to develop a commercially viable synthetic route to a known drug candidate. The approaches to a synthetic challenge are consequently very different to those used in medicinal chemistry. This Review uses case studies to highlight important considerations, and the tactics used during the design and selection of an efficient drug synthesis.

[1]  M. Schnaderbeck,et al.  Process Development of Halaven®: Synthesis of the C1–C13 Fragment from d-(–)-Gulono-1,4-lactone , 2013, Synlett.

[2]  Jinhua J. Song,et al.  Development of an asymmetric synthesis of a chiral quaternary FLAP inhibitor. , 2015, The Journal of organic chemistry.

[3]  M. Munchhof,et al.  Discovery of PF-04449913, a Potent and Orally Bioavailable Inhibitor of Smoothened. , 2012, ACS medicinal chemistry letters.

[4]  Jinhua J. Song,et al.  Addressing the configuration stability of lithiated secondary benzylic carbamates for the development of a noncryogenic stereospecific boronate rearrangement. , 2014, Organic letters.

[5]  R. Noyori,et al.  O-Selective Phosphorylation of Nucleosides without N-Protection. , 1993 .

[6]  Kathryn Graziano.  The innovator's dilemma: When new technologies cause great firms to fail , 1998 .

[7]  A. Skowron,et al.  Methodology and applications , 1998 .

[8]  Martin D. Eastgate,et al.  Mechanistic insights into the vanadium-catalyzed Achmatowicz rearrangement of furfurol. , 2015, The Journal of organic chemistry.

[9]  Martin D. Eastgate,et al.  Development of a Diastereoselective Phosphorylation of a Complex Nucleoside via Dynamic Kinetic Resolution. , 2015, The Journal of organic chemistry.

[10]  Bin Zheng,et al.  Ni-Catalyzed C-H Functionalization in the Formation of a Complex Heterocycle: Synthesis of the Potent JAK2 Inhibitor BMS-911543. , 2015, The Journal of organic chemistry.

[11]  T. Lindberg.  Strategies and Tactics in Organic Synthesis , 1993 .

[12]  A. Ros,et al.  Improved method for the conversion of pinacolboronic esters into trifluoroborate salts: facile synthesis of chiral secondary and tertiary trifluoroborates , 2009 .

[13]  G. Beutner,et al.  Scalable Synthesis of the Potent HIV Inhibitor BMS-986001 by Non-Enzymatic Dynamic Kinetic Asymmetric Transformation (DYKAT). , 2015, Angewandte Chemie.

[14]  Bin Zheng,et al.  Development of a Robust Process for the Preparation of High-Quality Dicyclopropylamine Hydrochloride , 2014 .

[15]  Martin D. Eastgate,et al.  Regioselective synthesis of 1,4-disubstituted imidazoles. , 2012, Organic & biomolecular chemistry.

[16]  I. Kola,et al.  Can the pharmaceutical industry reduce attrition rates? , 2004, Nature Reviews Drug Discovery.

[17]  Stephen Stinson,et al.  COUNTING ON CHIRAL DRUGS , 1998 .

[18]  Neal G. Anderson,et al.  Practical Process Research & Development , 2000 .

[19]  M. Kubota,et al.  Commercial Manufacture of Halaven®: Chemoselective Transformations En Route to Structurally Complex Macrocyclic Ketones , 2013, Synlett.

[20]  Chenchi Wang,et al.  Development of a Two-Step, Enantioselective Synthesis of an Amino Alcohol Drug Candidate , 2015 .

[21]  E. Hansen,et al.  Development of a concise, asymmetric synthesis of a smoothened receptor (SMO) inhibitor: enzymatic transamination of a 4-piperidinone with dynamic kinetic resolution. , 2014, Organic letters.

[22]  R. Soundararajan,et al.  Alkoxyalkyl)boronic Ester Intermediates for Asymmetric Synthesis , 1996 .

[23]  M. Kubota,et al.  Process Development of Halaven®: Synthesis of the C14–C35 Fragment via Iterative Nozaki–Hiyama–Kishi Reaction–Williamson Ether Cyclization , 2013 .

[24]  H. Brown,et al.  Chiral Synthesis via Organoboranes. Part 30. Facile Synthesis, by the Matteson Asymmetric Homologation Procedure, of α-Methyl Boronic Acids not Available from Asymmetric Hydroboration and Their Conversion into the Corresponding Aldehydes, Ketones, Carboxylic Acids, and Amines of High Enantiomeric Pu , 1991 .

[25]  T. Hense,et al.  Enantioselective Synthesis with Lithium/(−)‐Sparteine Carbanion Pairs , 1997 .

[26]  D. Hoppe,et al.  Chiral Lithium‐1‐oxyalkanides by Asymmetric Deprotonation; Enantioselective Synthesis of 2‐Hydroxyalkanoic Acids and Secondary Alkanols , 1990 .

[27]  H. Brown,et al.  Chiral synthesis via organoboranes. 30. Facile synthesis, by the Matteson asymmetric homologation procedure, of .alpha.-methyl boronic acids not available from asymmetric hydroboration and their conversion into the corresponding aldehydes, ketones, carboxylic acids, and amines of high enantiomeric p , 1991 .

[28]  Timothy J. N. Watson,et al.  Case Studies Illustrating a Science and Risk-Based Approach to Ensuring Drug Quality When Using Enzymes in the Manufacture of Active Pharmaceuticals Ingredients for Oral Dosage Form , 2016 .

[29]  Martin D. Eastgate,et al.  Regioselective bromination of fused heterocyclic N-oxides. , 2013, Organic letters.

[30]  Jinhua J. Song,et al.  Asymmetric synthesis of active pharmaceutical ingredients. , 2006, Chemical reviews.

[31]  J. Wiss,et al.  Safety Improvement of Chemical Processes Involving Azides by Online Monitoring of the Hydrazoic Acid Concentration , 2006 .

[32]  V. Aggarwal,et al.  Enantioselective construction of quaternary stereogenic centers from tertiary boronic esters: methodology and applications. , 2011, Angewandte Chemie.

[33]  Martin D. Eastgate,et al.  The Development of Scalable and Efficient Methods for the Preparation of Dicyclopropylamine HCl Salt , 2011 .

[34]  Jun Li,et al.  Current complexity: a tool for assessing the complexity of organic molecules. , 2015, Organic & biomolecular chemistry.

[35]  V. Aggarwal,et al.  Full chirality transfer in the conversion of secondary alcohols into tertiary boronic esters and alcohols using lithiation-borylation reactions. , 2010, Angewandte Chemie.

[36]  C H Senanayake,et al.  Asymmetric synthesis for process research. , 1999, Current opinion in drug discovery & development.

[37]  P. Beaulieu,et al.  Preparation of (2S,4R)-4-Hydroxypipecolic Acid and Derivatives. , 1996 .

[38]  Clayton M. Christensen.  The Innovator's Dilemma: When New Technologies Cause Great Firms to Fail , 2013 .

[39]  Stephen Stinson.  DELVING INTO DENDRIMERS , 1997 .

[40]  Stephen Stinson,et al.  PROTECTING GROUPS : NEW WAYS ON AND OFF , 1997 .

[41]  Long Pang,et al.  Case Studies Illustrating a Science and Risk-Based Approach to Ensuring Drug Quality When Using Enzymes in the Manufacture of Active Pharmaceuticals Ingredients for Oral Dosage Form , 2016 .

[42]  Martin D. Eastgate,et al.  A Method for Heteroaromatic Nitration Demonstrating Remarkable Thermal Stability , 2014 .

[43]  Jun Li,et al.  A Claisen approach to 4'-Ed4T. , 2015, Organic letters.

[44]  Martin D. Eastgate,et al.  Synthesis of the 6-azaindole containing HIV-1 attachment inhibitor pro-drug, BMS-663068. , 2014, The Journal of organic chemistry.

[45]  Gregory L. Finch,et al.  Use of Enzymes in the Manufacture of Active Pharmaceutical Ingredients—A Science and Safety-Based Approach To Ensure Patient Safety and Drug Quality , 2012 .

[46]  J. Emanuel,et al.  Breaking down the barriers , 2002, Nature.

[47]  S. Provera,et al.  Development of a Dynamic Kinetic Resolution for the Isolation of an Intermediate in the Synthesis of Casopitant Mesylate: Application of QbD Principles in the Definition of the Parameter Ranges, Issues in the Scale-Up and Mitigation Strategies , 2010 .

[48]  V. Aggarwal,et al.  Highly enantioselective synthesis of tertiary boronic esters and their stereospecific conversion to other functional groups and quaternary stereocentres. , 2011, Chemistry.

[49]  Paul N. Devine,et al.  Biocatalytic Asymmetric Synthesis of Chiral Amines from Ketones Applied to Sitagliptin Manufacture , 2010, Science.

[50]  C. Hang,et al.  Preparation of β-hydroxy-α-amino Acid Using Recombinant d-Threonine Aldolase , 2015 .

[51]  I. Marek,et al.  All-Carbon Quaternary Stereogenic Centers in Acyclic Systems Through the Creation of Several C—C Bonds per Chemical Step. , 2014 .

[52]  Jun Li,et al.  A data-driven strategy for predicting greenness scores, rationally comparing synthetic routes and benchmarking PMI outcomes for the synthesis of molecules in the pharmaceutical industry , 2017 .

[53]  V. Aggarwal,et al.  Enantiodivergent conversion of chiral secondary alcohols into tertiary alcohols , 2008, Nature.